AI-generated analysis. Always verify with the original filing.
Metagenomi Therapeutics, Inc. reported full year 2025 financial results including $25.2 million collaboration revenue, $94.4 million R&D expenses, and $87.9 million net loss, with $160.8 million in cash providing runway through 4Q 2027. The company completed pre-IND meeting for MGX-001 hemophilia A program and remains on track for IND submission in 4Q 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
(including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act o
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Earnings Press Release Issued by Metagenomi Therapeutics, Inc. on March 5, 2026 104
| Metric | Value | Basis |
|---|---|---|
| Collaboration revenue | $25.2K | GAAP |
| Research and development | $94.4K | GAAP |
| General and administrative | $26.8K | GAAP |
| Net loss | $87.9K | GAAP |